The HIV replication cycle includes integration of the reverse-transcribed viral genome into the host cell DNA where the provirus is retained for the life of the cell. Cellular machinery is used for proviral genetic expression, however, by means that are not fully understood, some HIV proviruses can maintain a latent, or transcriptionally-silent, state. It is thought that cells expressing HIV are susceptible to cell killing by cytopathic effects or immune responses. It stands to reason, therefore, that long-lived latently-infected cells may accumulate over the course of HIV infection and persist after ART is initiated. Indeed, many studies have demonstrated the persistence of latently-infected cells during ART and, it is believed that such cells carrying replication-competent proviruses, when activated, are the source of viral rebound when ART is interrupted. It was recently discovered that HIV infected T-cells can persist in vivo through cellular proliferation, which occurs both prior to and during ART. Several cases, thus far, have described highly expanded infected CD4+ T cell clones that were shown to be the source of persistent infectious viremia during ART. This talk will summarize emerging data from studies investigating HIV infected CD4+ T cell clones including their sites of HIV integration in blood and tissues both prior to and during ART, the fraction of HIV expressing cells within cell clones, including those carrying replication-competent proviruses, and explore new technologies for investigating HIV integration landscape and full-length proviral structures. Understanding the integration site landscape in cell clones that persist during ART will lead to a better understanding of the HIV reservoir, the nature of latency, and the sources of rebound viremia when ART is interrupted.